News
-
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: SYNBIOTIC SE (von NuWays AG): BUY
NuWays AG releases research on the classification of SYNBIOTIC SE, updating to a BUY recommendation with a target price of EUR 12.40. The group's performance is driven by strong results from WEECO Pharma and recent acquisitions -